ER signalling-dependent cancer cell growth is one of the major features of ER-positive (BC) [2], and endocrine therapies designed to block ER function, such as selective ER modulators and aromatase inhibitors [3], have been developed as adjuvant or neoadjuvant therapies for luminal BC. This evidence concerns the gene ESR1 and breast cancer.